{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:10:44Z","timestamp":1781680244799,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.tripleo.2004.08.020","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T01:37:00Z","timestamp":1103679420000},"page":"52-62","source":"Crossref","is-referenced-by-count":92,"title":["Oral effects of low-dose methotrexate treatment"],"prefix":"10.1016","volume":"100","author":[{"given":"Athanasios","family":"Kalantzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Marshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis T.","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W.","family":"Odell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tripleo.2004.08.020_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0162-3109(00)00184-3","article-title":"Methotrexate use in rheumatoid arthritis. A Clinician's perspective","volume":"47","author":"Alarcon","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.tripleo.2004.08.020_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tripleo.2004.08.020_bib3","article-title":"Methotrexate for rheumatoid arthritis","volume":"2","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Sys Rev"},{"key":"10.1016\/j.tripleo.2004.08.020_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","article-title":"Low-dose methotrexate in rheumatic diseases\u2014efficacy, side effects, and risk factors for side effects","volume":"5","author":"Schnabel","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/art.1780310203","article-title":"Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis","volume":"2","author":"Weinblatt","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0049-0172(05)80025-3","article-title":"Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis","volume":"1","author":"Giannini","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003129","article-title":"Methotrexate for treating juvenile idiopathic arthritis","volume":"3","author":"Takken","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tripleo.2004.08.020_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1542\/peds.109.1.109","article-title":"Current treatment of juvenile rheumatoid arthritis","volume":"1","author":"Ilowite","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.tripleo.2004.08.020_bib9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment","volume":"5","author":"Haustein","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00128071-200001010-00003","article-title":"Risk-benefit assessment of methotrexate in the treatment of severe psoriasis","volume":"1","author":"Kuijpers","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000212","article-title":"Interventions for psoriatic arthritis","volume":"3","author":"Jones","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tripleo.2004.08.020_bib12","first-page":"1730","article-title":"Methotrexate in Crohn's disease: long-term efficacy and toxicity","volume":"7","author":"Lemann","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1365-2036.2002.01227.x","article-title":"The efficacy of methotrexate for maintaining remission in inflammatory bowel disease","volume":"4","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.tripleo.2004.08.020_bib14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","volume":"22","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/rheumatology\/34.7.642","article-title":"Low-dose methotrexate: an effective corticosteriod-sparing agent in the musculoskeletal manifestations of sarcoidosis","volume":"7","author":"Kaye","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1378\/chest.112.1.29","article-title":"Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis","volume":"1","author":"Marin","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.tripleo.2004.08.020_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/sj.bmt.1704051","article-title":"Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan","volume":"2","author":"Koga","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.tripleo.2004.08.020_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0954-6111(98)90355-9","article-title":"Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials","volume":"92","author":"Aaron","year":"1998","journal-title":"Respir Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib19","article-title":"Methotrexate as a steroid sparing agent for asthma in adults","author":"Davies","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tripleo.2004.08.020_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1191\/096120301666080831","article-title":"Methotrexate therapy in systemic lupus erythematosus","volume":"3","author":"Sato","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.tripleo.2004.08.020_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH779>3.0.CO;2-8","article-title":"Localized and systemic scleroderma show different histological responses to methotrexate therapy","volume":"4","author":"Seyger","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0190-9622(97)70327-X","article-title":"Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis","volume":"1","author":"Kasteler","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s100720170026","article-title":"Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis","volume":"2","author":"Lugaresi","year":"2001","journal-title":"Neurol Sci"},{"key":"10.1016\/j.tripleo.2004.08.020_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1076\/ocii.9.1.35.3983","article-title":"Use of methotrexate in the management of sight-threatening uveitis","volume":"1","author":"Bom","year":"2001","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.tripleo.2004.08.020_bib25","series-title":"Arthritis & allied conditions. A textbook of rheumatology","first-page":"679","article-title":"Methotrexate: its use for the treatment of rheumatoid arthritis and other rheumatic disorders","author":"Alarcon","year":"1997"},{"key":"10.1016\/j.tripleo.2004.08.020_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/rheumatology\/XXXIV.suppl_4.20","article-title":"Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis","volume":"34 Suppl 2","author":"Furst","year":"1995","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0049-0172(98)80049-8","article-title":"Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity","volume":"5","author":"van Ede","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"2-3","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.tripleo.2004.08.020_bib29","first-page":"459","article-title":"Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients","volume":"4","author":"Leeb","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"8","author":"Cutolo","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.tripleo.2004.08.020_bib31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780310501","article-title":"A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months","volume":"5","author":"Kremer","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00008571-200204000-00002","article-title":"Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses","volume":"3","author":"Urano","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.tripleo.2004.08.020_bib33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0889-857X(05)70367-7","article-title":"The remarkable spectrum of methotrexate toxicities","volume":"4","author":"McKendry","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.tripleo.2004.08.020_bib34","first-page":"978","article-title":"The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study","volume":"7","author":"Mielants","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib35","first-page":"205","article-title":"The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis","volume":"2","author":"Thumboo","year":"1997","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.tripleo.2004.08.020_bib36","first-page":"1850","article-title":"Adverse effects of low dose methotrexate therapy in rheumatoid arthritis","volume":"11","author":"McKendry","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib37","first-page":"23","article-title":"A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis","volume":"1","author":"Salaffi","year":"1995","journal-title":"Clin Exper Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib38","first-page":"307","article-title":"Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study","volume":"3","author":"Fehlauer","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib39","first-page":"994","article-title":"Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts","volume":"8","author":"Wolfe","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"7","author":"Williams","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/anr.1780320603","article-title":"Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment","volume":"32","author":"Alarcon","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s001050050979","article-title":"[Ulcerative stomatitis as clinical clue to inadvertent methotrexate overdose.]","volume":"50","author":"Bauer","year":"1999","journal-title":"Hautarzt"},{"key":"10.1016\/j.tripleo.2004.08.020_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5694\/j.1326-5377.1994.tb127348.x","article-title":"Low dose methotrexate therapy\u2014toxic if not taken correctly. Adverse Drug Reactions Advisory Committee","volume":"161","author":"Anonymous","year":"1994","journal-title":"Med J Aust"},{"key":"10.1016\/j.tripleo.2004.08.020_bib44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.1992.03490150083021","article-title":"Errors in prescribing methotrexate","volume":"15","author":"Lomaestro","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.tripleo.2004.08.020_bib45","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0190-9622(93)70069-6","article-title":"Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis","volume":"3","author":"Duhra","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib46","first-page":"477","article-title":"Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths)","volume":"62","author":"Berthelot","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.tripleo.2004.08.020_bib47","first-page":"243","article-title":"Drug-induced pneumonitis: the role of methotrexate","volume":"3","author":"Zisman","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.tripleo.2004.08.020_bib48","first-page":"10","article-title":"Disease modifying antirheumatic drugs: longterm safety issues","volume":"62","author":"Capell","year":"2001","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.tripleo.2004.08.020_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s003930070036","article-title":"Rheumatoid arthritis and osteoporosis","volume":"59 Suppl 1","author":"Westhovens","year":"2000","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","article-title":"Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density","volume":"7","author":"Minaur","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.tripleo.2004.08.020_bib51","first-page":"2395","article-title":"The effect of low dose methotrexate on bone density","volume":"11","author":"Cranney","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib52","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0049-0172(95)80009-3","article-title":"Infections during low-dose methotrexate treatment in rheumatoid arthritis","volume":"24","author":"Boerbooms","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0889-857X(05)70368-9","article-title":"Does methotrexate increase the risk of infection or malignancy?","volume":"4","author":"Kanik","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.tripleo.2004.08.020_bib54","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1445-5994.1995.tb02851.x","article-title":"Hazards of low dose methotrexate","volume":"6","author":"Conaghan","year":"1995","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatment of rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib56","first-page":"267","article-title":"Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate","volume":"4","author":"Sibilia","year":"1998","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.tripleo.2004.08.020_bib57","first-page":"1628","article-title":"Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis","volume":"12","author":"Furst","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib58","first-page":"153","article-title":"Low dose treatment with methotrexate-adverse drug reactions survey","volume":"4","author":"Getov","year":"2000","journal-title":"Boll Chim Farm"},{"key":"10.1016\/j.tripleo.2004.08.020_bib59","first-page":"146","article-title":"Side effects of 15mg and 25mg methotrexate\/week for rheumatoid arthritis","volume":"5","author":"Schnabel","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/mpo.2950170514","article-title":"Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia","volume":"5","author":"Ishii","year":"1989","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00007691-199506000-00006","article-title":"Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases","volume":"3","author":"Press","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.tripleo.2004.08.020_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/08880019609030842","article-title":"Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate","volume":"4","author":"Rask","year":"1996","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00001813-199702000-00003","article-title":"Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis","volume":"2","author":"Albertioni","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tripleo.2004.08.020_bib64","first-page":"268","article-title":"Oral mucous membrane lesions in children treated with bone marrow transplantation","volume":"3","author":"Dahllof","year":"1989","journal-title":"Scand J Dent Res"},{"key":"10.1016\/j.tripleo.2004.08.020_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/00220345700490032501","article-title":"Studies on the biology of the periodontium of marmosets: 8. The effect of folic acid deficiency on the marmoset oral mucosa","volume":"3","author":"Dreizen","year":"1970","journal-title":"J Dent Res"},{"key":"10.1016\/j.tripleo.2004.08.020_bib66","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1600-0765.1994.tb01240.x","article-title":"Effect of long-term methotrexate-induced neutropenia on experimental periodontal lesion in rats","volume":"6","author":"Yoshinari","year":"1994","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.tripleo.2004.08.020_bib67","first-page":"129","article-title":"Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines","volume":"3","author":"Endresen","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib68","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tripleo.2004.08.020_bib69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780290602","article-title":"Survival, prognosis and causes of death in rheumatoid arthritis","volume":"29","author":"Mitchell","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib70","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1001\/jama.286.22.2787","article-title":"Progress in the treatment of rheumatoid arthritis","volume":"22","author":"Pisetsky","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tripleo.2004.08.020_bib71","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/1529-0131(199910)42:10<2160::AID-ANR17>3.0.CO;2-T","article-title":"Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study","volume":"10","author":"Luis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.1780351003","article-title":"Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials","volume":"10","author":"Felson","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.1989.00390030137027","article-title":"Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients","volume":"3","author":"McKendry","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib74","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/39.9.975","article-title":"Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs","volume":"9","author":"Maetzel","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.tripleo.2004.08.020_bib75","doi-asserted-by":"crossref","first-page":"294","DOI":"10.12968\/hosp.2002.63.5.2023","article-title":"Advances in the medical management of rheumatoid arthritis","volume":"5","author":"Scott","year":"2002","journal-title":"Hosp Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib76","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease-modifying agents in rheumatoid arthritis","volume":"8","author":"Kremer","year":"2001","journal-title":"Ann Int Med"},{"key":"10.1016\/j.tripleo.2004.08.020_bib77","first-page":"50","article-title":"Quantitative criteria of folate deficiency in cervico-vaginal cytograms, with report of a new parameter","volume":"1","author":"Klaus","year":"1971","journal-title":"Acta Cytol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib78","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jama.1973.03230120013003","article-title":"Megaloblastic changes in cervical epithelium. Association with oral contraceptive therapy and reversal with folic acid","volume":"226","author":"Whitehead","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.tripleo.2004.08.020_bib79","first-page":"189","article-title":"Diagnosis and early endometrial cancer and precancerous states","volume":"3","author":"Koss","year":"1979","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.tripleo.2004.08.020_bib80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B","article-title":"TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis","volume":"2","author":"Valente","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tripleo.2004.08.020_bib81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1383-5718(98)00104-1","article-title":"Micronuclei in lymphocytes and exfoliated buccal cells of postmenopausal women with dietary changes in folate","volume":"417","author":"Titenko-Holland","year":"1998","journal-title":"Mutat Res"},{"key":"10.1016\/j.tripleo.2004.08.020_bib82","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.1992.tb17091.x","article-title":"Localized deficiencies of folic acid in aerodigestive tissues","volume":"669","author":"Heimburger","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.tripleo.2004.08.020_bib83","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0030-4220(77)90108-6","article-title":"Nuclear characteristics of buccal mucosa cells in sickle-cell anemia","volume":"43","author":"Hays","year":"1977","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib84","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/00000478-200105000-00013","article-title":"Bizarre epithelial atypia of the sinonasal tract","volume":"25","author":"Westra","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib85","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tripleo.2004.08.020_bib86","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0002-9343(99)80160-0","article-title":"Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study","volume":"99","author":"Moder","year":"1995","journal-title":"Am J Med"},{"issue":"5-6","key":"10.1016\/j.tripleo.2004.08.020_bib87","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/10428199509054421","article-title":"Immunosuppression-associated lymphoproliferative disorders in rheumatic patients","volume":"16","author":"Kamel","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.tripleo.2004.08.020_bib88","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM199311253292216","article-title":"Reversible lymphomas","volume":"329","author":"Shiroky","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.tripleo.2004.08.020_bib89","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00002018-199920060-00002","article-title":"Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?","volume":"20","author":"Georgescu","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.tripleo.2004.08.020_bib90","unstructured":"Bulletin Board of Oral Pathology. Available at: http:\/\/www.sdm.buffalo.edu\/bbop\/. Accessed December 1, 2004."},{"key":"10.1016\/j.tripleo.2004.08.020_bib91","first-page":"860","article-title":"Low dose methotrexate in rheumatoid arthritis","volume":"9","author":"Steinsson","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib92","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/art.1780250312","article-title":"Weekly intravenous methotrexate in the treatment of rheumatoid arthritis","volume":"25","author":"Michaels","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tripleo.2004.08.020_bib93","first-page":"760","article-title":"A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis","volume":"11","author":"Thompson","year":"1984","journal-title":"J Rheumatol"},{"key":"10.1016\/j.tripleo.2004.08.020_bib94","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0002-9343(85)90312-2","article-title":"Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations","volume":"79","author":"Weinstein","year":"1985","journal-title":"Am J Med"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210404006080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210404006080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T21:37:19Z","timestamp":1586036239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210404006080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1079210404006080"],"URL":"https:\/\/doi.org\/10.1016\/j.tripleo.2004.08.020","relation":{},"ISSN":["1079-2104"],"issn-type":[{"value":"1079-2104","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}